Molbio Diagnostics has expanded the global footprint of its Truenat platform, now exported to over 85 countries and patented in more than 100. Truenat, the only rapid molecular TB test developed by an Indian company, supports diagnosis of 30 diseases with 42 assays and is widely used in low-resource settings for fast, decentralised testing. Molbio’s operational revenue rose 22% in FY25 to ₹1,020.4 crore, with over 10,000 Truenat devices deployed globally. The company has filed for an IPO, aiming to raise ₹200 crore to enhance its R&D and manufacturing capabilities, and recently acquired a strategic stake in US-based OptraScan to expand into digital pathology.